Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relmada Therapeutics (RLMD) Total Liabilities (2016 - 2026)

Relmada Therapeutics has reported Total Liabilities over the past 3 years, most recently at $41155.0 for Q1 2014.

  • Quarterly Total Liabilities rose 242.9% to $41155.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $41155.0 through Feb 2014, up 242.9% year-over-year, with the annual reading at $33666.0 for FY2013, 381.22% up from the prior year.
  • Total Liabilities was $41155.0 for Q1 2014 at Relmada Therapeutics, up from $40331.0 in the prior quarter.
  • Over five years, Total Liabilities peaked at $41155.0 in Q1 2014 and troughed at $6996.0 in Q3 2012.
  • The 3-year median for Total Liabilities is $29846.0 (2013), against an average of $26696.0.
  • Year-over-year, Total Liabilities soared 381.22% in 2013 and then skyrocketed 242.9% in 2014.
  • A 3-year view of Total Liabilities shows it stood at $6996.0 in 2012, then surged by 476.49% to $40331.0 in 2013, then increased by 2.04% to $41155.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Total Liabilities are $41155.0 (Q1 2014), $40331.0 (Q4 2013), and $33666.0 (Q3 2013).